Chlamydia Infections (Infectious Disease) - Drugs In Development, 2021

July 2021 | 90 pages | ID: C73BD634045FEN
Global Markets Direct

Abstracts

Chlamydia Infections (Infectious Disease) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Drugs In Development, 2021, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.

Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Chlamydia Infections - Overview
Chlamydia Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chlamydia Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chlamydia Infections - Companies Involved in Therapeutics Development
Abera Bioscience AB
Abivax SA
BlueWillow Biologics Inc
Erganeo
Eurocine Vaccines AB
Evofem Biosciences Inc
Genetic Immunity Inc
Lead Discovery Center GmbH
Merck & Co Inc
Microbiotix Inc
QureTech Bio AB
Traccine Pharmaceuticals
Vault Pharma Inc
Vaxine Pty Ltd
Yaso Therapeutics Inc
Chlamydia Infections - Drug Profiles
(citric acid + lactic acid + potassium bitartrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ab-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABX-196 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ChlamyDerm - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEG-2S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit CPAF for Chlamydia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPCM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chlamydia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPI-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia Infections - Dormant Projects
Chlamydia Infections - Product Development Milestones
Featured News & Press Releases
May 17, 2021: New data on EVO100 for the prevention of chlamydia and gonorrhea in women to be presented at ISPOR 2021
Mar 31, 2021: Eurocine Vaccines initiates process development of the vaccine candidate against chlamydia
Mar 16, 2021: Evofem Biosciences announces publication in American Journal of Obstetrics and Gynecology of AMPREVENCE study of EVO100 for chlamydia and gonorrhea prevention
Feb 25, 2021: Eurocine Vaccines confirms good immunological effect in preclinical study with the chlamydia vaccine candidate
Dec 30, 2020: Eurocine Vaccines advances the development of commercial manufacturing method and updates time plan
Dec 30, 2020: Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate
Dec 22, 2020: Evofem Biosciences to participate in Medicaid National Drug Rebate Program for Phexxi effective January 1, 2021
Dec 21, 2020: Evofem Biosciences to present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
Dec 17, 2020: Evofem Biosciences provides update on pivotal phase 3 trial of EVO100 for prevention of chlamydia and gonorrhea
Dec 11, 2020: Evofem Biosciences announces orange book listing of two U.S. patents for Phexxi
Dec 03, 2020: The U.S. Department of Veterans Affairs awards contract to Evofem Biosciences for Phexxi
Oct 20, 2020: Evofem Biosciences announces first patient enrolled in pivotal phase 3 trial of EVO100 for prevention of chlamydia and gonorrhea
Sep 14, 2020: Evofem Biosciences to present data at the 2020 STD prevention virtual conference from phase 2b trial of EVO100 for prevention of chlamydia and gonorrhea in women
May 12, 2020: Eurocine Vaccines receives notification of grant to prepare for the manufacture of the chlamydia vaccine candidate
May 07, 2020: Eurocine Vaccines presents end results from preclinical study with chlamydia vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Chlamydia Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Chlamydia Infections - Pipeline by Abera Bioscience AB, 2021
Chlamydia Infections - Pipeline by Abivax SA, 2021
Chlamydia Infections - Pipeline by BlueWillow Biologics Inc, 2021
Chlamydia Infections - Pipeline by Erganeo, 2021
Chlamydia Infections - Pipeline by Eurocine Vaccines AB, 2021
Chlamydia Infections - Pipeline by Evofem Biosciences Inc, 2021
Chlamydia Infections - Pipeline by Genetic Immunity Inc, 2021
Chlamydia Infections - Pipeline by Lead Discovery Center GmbH, 2021
Chlamydia Infections - Pipeline by Merck & Co Inc, 2021
Chlamydia Infections - Pipeline by Microbiotix Inc, 2021
Chlamydia Infections - Pipeline by QureTech Bio AB, 2021
Chlamydia Infections - Pipeline by Traccine Pharmaceuticals, 2021
Chlamydia Infections - Pipeline by Vault Pharma Inc, 2021
Chlamydia Infections - Pipeline by Vaxine Pty Ltd, 2021
Chlamydia Infections - Pipeline by Yaso Therapeutics Inc, 2021
Chlamydia Infections - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chlamydia Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021